has invited you to join this group
Professor of Pediatrics in Infectious Diseases at University of Tennessee School of Medicine
Physician at AstraZeneca, USA
Neonatologist in Italy
Vice President, Global Franchise Head, Infection at AstraZeneca, USA
Neonatal Clinician Scientist at Imperial College London and Chelsea and Westminster Hospital
Professor of Neonatal Medicine at Imperial College London
Consultant Neonatologist ( Physician) at Chelsea and Westminster Hospital NHS Foundation Trust
Consultant Neonatologist at Chelsea and Westminster Hospital
Neonatal Clinician Scientist at Imperial College London
Neonatal Clinical Trials Statistician at Imperial College London
Clinical Senior Lecturer and Consultant in Neonatal Medicine at Chelsea and Westminster Hospital NHS Foundation Trust
Consultant Neonatologist at Chelsea and Westminster Hospital
Statistician at Imperial College London
Consultant Neonatologist at Chelsea and Westminster Hospital NHS Foundation Trust
Consultant Neonatologist and Service Director, Neonatology at Chelsea and Westminster Hospital
Resident in Neonatal-Perinatal Medicine at Chelsea and Westminster
Paediatric doctor
Neonatal SHO at Chelsea and Westminster Hospital
Resident in Neonatal-Perinatal Medicine at Chelsea and Westminster Hospital Neonatal Training Programme
Resident in Neonatal-Perinatal Medicine at Chelsea and Westminster Hospital Neonatal Training Programme
Fellow in Neonatology
Resident in Neonatal-Perinatal Medicine at Imperial College London, Chelsea and Westminster Hospital
Resident in Neonatal-Perinatal Medicine at Chelsea and Westminster Hospital Neonatal Training Programme
Neonatal and Perinatal Doctor with a special interest in everything associated with babies
Chief Resident in Neonatal-Perinatal Medicine at Neonatal GRID training
Resident in Neonatal-Perinatal Medicine at Chelsea and Westminster
I'd be interested to know how you, as the authors, would summarise the strengths and weaknesses of your study? And what questions you think still need to be answered for the clinical impact of Nirsevimab to be fully understood (besides Nirsevimab vs. Palivuzimab given the previous reply)?
Log in or create an account to comment
Social Login
Email Login
Log in via Email
Back to Social Login
Create Your Account